Clinical trial BOS172738
A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1 |
Academic trial | Non |
Sponsor | Boston pharmaceuticals |
EudraCT Identifier | 2018-002612-27 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03780517 |
Inclusion criteria | Rearranged during transfection(RET) gene altered malignancy |
Last update |